Researchers at Tulane University are reporting on how cancer is able to overcome p53, a key tumor-suppressing protein.
Genetic profiling combined with clinical factors may help guide clinicians on how to better manage patients with myelodysplastic syndrome.
Researchers at Johns Hopkins Kimmel Cancer Center have been studying the ability of a novel panel of cell-free DNA methylation markers to predict survival in women with metastatic breast cancer.
Oncologists today now have a much greater understanding of the mutational landscape underlying some tumors. However, in many respects it is still a daunting task—one that may require more effective interpretation tools.
A new study is suggesting that by targeting a specific microRNA molecule (miR-141) it may be possible to stop the cascade of events that lead to metastasis in men with prostate cancer.
A study just published in Cancer Cell is suggesting a new target for combating KRAS-mediated lung adenocarcinoma.
A new German multicenter study is suggesting that lutetium-177 (Lu-177)-labeled PSMA-617 may be a promising new therapeutic agent for radioligand therapy in men with metastatic castration-resistant prostate cancer.
A new study is suggesting it may be possible to shut down the circuits that drive the high tumorigenicity of prostate cancer cells leading to castration-resistant prostate cancer.
A study recently published is suggesting that a key drug target, CDK4/6, regulates a cancer metastasis protein, and may play a role in combating metastasis in triple-negative breast cancer. In addition, this new finding may point to a new way of preventing metastasis in other cancers.
An anti-HER2 dendritic vaccination may be a safe and immunogenic treatment to induce tumor-specific T-cell responses in HER2-positive, early-stage breast cancer patients.